Primary and secondary hypothyroidism
Primary and secondary hypothyroidism
Thyroid gland
Thyroid gland

Hypothyroidism - secondary

Definition:
Secondary hypothyroidism involves decreased activity of the thyroid caused by failure of the pituitary gland.

Alternative Names:
Pituitary hypothyroidism

Causes, incidence, and risk factors:

The thyroid gland is an important organ of the endocrine system, located in the front of the neck just below the voicebox. The thyroid secretes the hormones thyroxine (T4), triiodothyronine (T3), and calcitonin, which control body metabolism and regulate calcium balance.

The secretion of T3 and T4 by the thyroid is controlled by an endocrine feedback system involving the pituitary gland and the hypothalamus (part of the brain). Lowered levels of these thyroid hormones result in increased levels of pituitary and hypothalamic hormones and vice versa, helping keep levels appropriately balanced. Calcitonin is regulated by the amount of calcium in the blood and acts in conjunction with the parathyroid gland to control calcium levels.

Since the thyroid gland is regulated by the pituitary gland and the hypothalamus, thyroid disorders may result not only from defects in the thyroid itself but also from the disruption of the control system in these other organs.

Thyroid disorders caused by overproduction of thyroid hormones are called hyperthyroidism, and underproduction of these hormones is known as hypothyroidism.

The cause of secondary hypothyroidism is failure of the pituitary gland to secrete thyroid stimulating hormone (TSH). This is usually caused by a tumor in the region of the pituitary. Rarely the cause is an infiltration of the pituitary by inflammatory cells from the immune system or foreign substances (such as iron in hemochromotosis).

Hypothyroidism may cause a variety of symptoms and can affect all body functions. The body's normal rate of functioning slows, causing mental and physical sluggishness. Symptoms vary from mild to severe. The most severe form is called myxedema, which is a medical emergency and can lead to coma and death.

Risk factors for secondary hypothyroidism include being over 50 years old, being female, and having a history of pituitary or hypothalamic dysfunction.

Symptoms:
Early symptoms: Late symptoms:
Signs and tests:
A physical exam usually reveals a small thyroid gland. Vital signs (temperature, pulse, rate of breathing, blood pressure) reveal a slow heart rate, low blood pressure, and low temperature.

A chest X-ray may reveal an enlarged heart.

Laboratory tests to determine thyroid function include:
  • Free T4 test
  • Total T3
  • Serum TSH -- Results are generally low in secondary hypothyroidism because the pituitary is damaged. However, normal or even high values may be seen.

Additional laboratory abnormalities may include:

Imaging will include an MRI of the pituitary to look for a tumor.

Treatment:

The purpose of treatment is to replace the deficient thyroid hormone. Levothyroxine is the most commonly used medication. The lowest dose effective in normalizing thyroid function is used. Life-long therapy may be necessary. Medication must be continued even when symptoms subside.

After replacement therapy has begun, report any symptoms of increased thyroid activity (hyperthyroidism), such as restlessness, rapid weight loss, and sweating.

A high-fiber, low-calorie diet and moderate activity will help relieve constipation and promote weight loss if weight was gained during the time when thyroid activity was low.

In individuals with accompanying hypoadrenalism, steroid replacement must be instituted before thyroid replacement is begun.

In patients who have hypothyroidism caused by a pituitary tumor, surgery may be required. However, surgery may not cure the hypothyroidism, and thyroid replacement will still be needed.

Myxedema coma is treated by intravenous (IV) thyroid replacement and steroid therapy. Supportive therapy of oxygen, assisted ventilation, fluid replacement, and intensive care nursing may be indicated.

Expectations (prognosis):
With early treatment, return to the normal state is usual. However, relapses will occur if the medication is not continued. Myxedema coma can result in death.
Complications:
Myxedema coma, the most severe form of hypothyroidism, is rare. It may be precipitated by an infection, illness, exposure to cold, or certain medications.

Symptoms and signs of myxedema coma include: Other complications include:
Calling your health care provider:

Call your health care provider if signs of hypothyroidism are present, or if chest pain or rapid heartbeat occur.

Call your health care provider if restlessness, rapid weight loss, sweating, or other symptoms occur after beginning treatment for this disorder.

Call your health care provider if headache, visual loss, or breast discharge occur.

Prevention:
This condition may not be preventable. Awareness of risk may allow early diagnosis and treatment.

Review Date: 7/24/2002
Reviewed By: Todd T. Brown, M.D., Division of Endocrinology and Metabolism, Johns Hopkins Hospital, Baltimore, MD. Review provided by VeriMed Healthcare Network.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is the first of its kind, requiring compliance with 53 standards of quality and accountability, verified by independent audit. A.D.A.M. is among the first to achieve this important distinction for online health information and services. A.D.A.M. is also a founding member of Hi-Ethics (www.hiethics.com) and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed physician should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. Copyright 2003 A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.